Literature DB >> 25452437

Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.

Melinda L Irwin1, Brenda Cartmel2, Cary P Gross2, Elizabeth Ercolano2, Fangyong Li2, Xiaopan Yao2, Martha Fiellin2, Scott Capozza2, Marianna Rothbard2, Yang Zhou2, Maura Harrigan2, Tara Sanft2, Kathryn Schmitz2, Tuhina Neogi2, Dawn Hershman2, Jennifer Ligibel2.   

Abstract

PURPOSE: Arthralgia occurs in up to 50% of breast cancer survivors treated with aromatase inhibitors (AIs) and is the most common reason for poor AI adherence. We conducted, in 121 breast cancer survivors receiving an AI and reporting arthralgia, a yearlong randomized trial of the impact of exercise versus usual care on arthralgia severity. PATIENTS AND METHODS: Eligibility criteria included receiving an AI for at least 6 months, reporting ≥ 3 of 10 for worst joint pain on the Brief Pain Inventory (BPI), and reporting < 90 minutes per week of aerobic exercise and no strength training. Participants were randomly assigned to exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week) or usual care. The BPI, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, and Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire were completed at baseline and at 3, 6, 9, and 12 months. Intervention effects were evaluated using mixed-model repeated measures analysis, with change at 12 months as the primary end point.
RESULTS: Over 12 months, women randomly assigned to exercise (n = 61) attended 70% (± standard deviation [SD], 28%) of resistance training sessions and increased their exercise by 159 (± SD, 136) minutes per week. Worst joint pain scores decreased by 1.6 points (29%) at 12 months among women randomly assigned to exercise versus a 0.2-point increase (3%) among those receiving usual care (n = 60; P < .001). Pain severity and interference, as well as DASH and WOMAC pain scores, also decreased significantly at 12 months in women randomly assigned to exercise, compared with increases for those receiving usual care (all P < .001).
CONCLUSION: Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivors.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25452437      PMCID: PMC4372849          DOI: 10.1200/JCO.2014.57.1547

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

1.  St. Gallen 2011: Summary of the Consensus Discussion.

Authors:  Michael Gnant; Nadia Harbeck; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 2.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

3.  Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians.

Authors:  A M Kriska; W C Knowler; R E LaPorte; A L Drash; R R Wing; S N Blair; P H Bennett; L H Kuller
Journal:  Diabetes Care       Date:  1990-04       Impact factor: 19.112

4.  Aerobic training increases pain tolerance in healthy individuals.

Authors:  Matthew D Jones; John Booth; Janet L Taylor; Benjamin K Barry
Journal:  Med Sci Sports Exerc       Date:  2014-08       Impact factor: 5.411

5.  A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.

Authors:  Jun J Mao; Sharon X Xie; John T Farrar; Carrie T Stricker; Marjorie A Bowman; Deborah Bruner; Angela DeMichele
Journal:  Eur J Cancer       Date:  2013-10-24       Impact factor: 9.162

Review 6.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

7.  Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

Authors:  Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar
Journal:  Lancet Oncol       Date:  2008-08-12       Impact factor: 41.316

8.  Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.

Authors:  B Oh; B Kimble; D S J Costa; E Davis; A McLean; K Orme; J Beith
Journal:  Acupunct Med       Date:  2013-05-30       Impact factor: 2.267

9.  Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.

Authors:  Katherine D Crew; Jillian L Capodice; Heather Greenlee; Lois Brafman; Deborah Fuentes; Danielle Awad; Wei Yann Tsai; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Cardiorespiratory fitness in breast cancer patients: a call for normative values.

Authors:  Amanda B Peel; Samantha M Thomas; Kim Dittus; Lee W Jones; Susan G Lakoski
Journal:  J Am Heart Assoc       Date:  2014-01-13       Impact factor: 5.501

View more
  66 in total

Review 1.  Physical Activity, Exercise and Breast Cancer - What Is the Evidence for Rehabilitation, Aftercare, and Survival? A Review.

Authors:  Petra Wirtz; Freerk T Baumann
Journal:  Breast Care (Basel)       Date:  2018-04-11       Impact factor: 2.860

2.  Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.

Authors:  Tera L Fazzino; Jennifer Klemp; Christie Befort
Journal:  Breast Cancer Res Treat       Date:  2017-12-22       Impact factor: 4.872

3.  Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis.

Authors:  Martina E Schmidt; Joachim Wiskemann; Karen Steindorf
Journal:  Qual Life Res       Date:  2018-05-08       Impact factor: 4.147

4.  Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).

Authors:  Arlene Chan; R De Boer; A Gan; P Willsher; R Martin; Y Zissiadis; K Miller; A Bauwens; D Hastrich
Journal:  Support Care Cancer       Date:  2017-07-09       Impact factor: 3.603

5.  Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Authors:  Andrea Sitlinger; Rebecca A Shelby; Alyssa N Van Denburg; Heidi White; Sarah N Edmond; Paul K Marcom; Hayden B Bosworth; Francis J Keefe; Gretchen G Kimmick
Journal:  J Geriatr Oncol       Date:  2018-12-13       Impact factor: 3.599

6.  Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.

Authors:  N Lynn Henry; Kelly Speth; Anneleen Lintermans; Kelley M Kidwell; Rachel Carlson; Daniel F Hayes; Patrick Neven
Journal:  Clin Breast Cancer       Date:  2017-03-11       Impact factor: 3.225

7.  Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Jinbo Chen; Jun J Mao
Journal:  Eur J Cancer       Date:  2018-01-09       Impact factor: 9.162

8.  Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Authors:  Sherry Shen; Joseph M Unger; Katherine D Crew; Cathee Till; Heather Greenlee; Julie Gralow; Shaker R Dakhil; Lori M Minasian; James L Wade; Michael J Fisch; N Lynn Henry; Dawn L Hershman
Journal:  Breast Cancer Res Treat       Date:  2018-08-29       Impact factor: 4.872

9.  Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Robert Gross; Jinbo Chen; Jun J Mao
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

Review 10.  Chemotherapy-Related Neurotoxicity.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.